Navigation Links
Adherence of Nanoparticles to RBC- Very Effective Drug Delivery Method

Researchers at the University of California, have discovered that attaching polymeric nanoparticles to the surface of red blood cells dramatically increases the in vivo lifetime of the nanoparticles.

Polymeric nanoparticles are excellent carriers for delivering drugs. They protect drugs from degradation until they reach their target and provide sustained release of drugs. Polymeric nanoparticles, however, suffer from one major limitation: they are quickly removed from the blood, sometimes in minutes, rendering them ineffective in delivering drugs.

The research team, led by Samir Mitragotri, a professor of chemical engineering, and Elizabeth Chambers, a recent doctoral graduate, found that nanoparticles can be forced to remain in the circulation when attached to red blood cells.

The particles eventually detach from the blood cells due to shear forces and cell-to-cell interactions, and are cleared from the system by the liver and spleen. Red blood cell circulation is not affected by attaching the nanoparticles.

Attachment of polymeric nanoparticles to red blood cells combines the advantages of the long circulating lifetime of the red blood cell, and their abundance, with the robustness of polymeric nanoparticles, said Mitragotri. Using red blood cells to extend the circulation time of the particles avoids the need to modify the surface chemistry of the entire particle, which offers the potential to attach chemicals to the exposed surface for targeting applications.

The researchers have learned that particles adhered to red blood cells can escape phagocytosis because red blood cells have a knack for evading macrophages. Nanoparticles arent the first to be piggybacking on red blood cells; the strategy has already been adopted by certain bacteria, such as hemobartonella, that adhere to RBCs and can remain in circulation for several weeks.

The researchers say that it may be possible to keep the nanopartic les in circulation for a relatively long time, theoretically up to the circulation lifetime of a red blood cell which is 120 days if the binding between particles and the red blood cells is strengthened. The methodology is applicable to drugs that are effective while still attached to a red blood cell, although the researchers say that slow release from the red blood cell surface is also feasible.

Mitragotri says this mode of prolonging particle circulation has significant implications in drug delivery, potentially leading to new treatments for a broad variety of conditions such as cancer, blood clots and heart disease. Dr. Steven R. Goodman, Editor-in-Chief of the journal, said this study dealing with the attachment of nanoparticles to red blood cells may also have important implications for future treatment of hematologic disorders.

This fusion of modern nanobioscience with cell biology and hematology is precisely the type of interdisciplinary study that the new Experimental Biology and Medicine is interested in publishing. Experimental Biology and Medicine is a journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences.


'"/>




Related medicine news :

1. Adherence to Dietary Recommendations Measured
2. Medication Adherence - Influenced by Drug or Race?
3. Sub-Saharan Africans With HIV May Achieve Favorable Levels of ART Adherence
4. Pharmacy Care Program Can Increase Medication Adherence in Elderly
5. Study Finds No Correlation Between Number of Pills and Adherence to It
6. Gold Nanoparticles: Agents For Noninvasive Cancer Therapy
7. Alzheimers Can Be Slowed Down By Gold Nanoparticles
8. Gold Nanoparticles Are Good Detectors Biological Toxins
9. Scientists To Study Effect Of Nanoparticles On Liver
10. Nanoparticles and Their Damage to Liver Cells
11. Effect of Nanoparticles on Liver
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: